Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Glo-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Recruiting

2024-510575-38-00 Relapsed and refractory mature B-cell non-Hodgkin Lymph 10 2026-02-24
Multimodal Imaging with FAPI-PET/MRI in Breast Carcinoma-In-Situ for Detection of occult Invasive cancer (MI-CISDIR) Recruiting

2023-509860-47-00 Ductal carcinoma in situ 4 2026-02-20
A Phase 1 Study for ZW191 in Participants with Solid Tumors Recruiting

2024-512299-37-00 Advanced solid tumors 1 2026-02-18
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adult… Recruiting

2025-522184-15-00 Advanced Solid Tumor, Metastatic Solid Tumor 7 2026-02-18
A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting

2024-511362-37-00 Non squamous non-small cell lung cancer (NSCLC) 5 2026-02-18
A Phase 1, First-in-Human Study of MEN2312, a KAT6 inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer Recruiting

2024-514661-19-01 Advanced ER+/HER2- Breast Cancer 1 2026-02-18
A Clinical Trial to learn about the effects of TLN-372 when given Alone and in Combination with Other Anti-Tumor Agents in people with Advan… Recruiting

2025-523086-22-00 Locally advanced or metastatic solid tumors 7 2026-02-18
Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting

2025-521805-41-00 Patients with HER2-positive, locally advanced or metast 5 2026-02-18
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer Recruiting

2025-521904-23-00 Locally Advanced Inoperable or Metastatic Breast Cancer 4 2026-02-17
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (… Recruiting

2025-523101-15-00 Relapsed or Refractory Acute Myeloid Leukemia or Higher 1 2026-02-16
A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped respon… Recruiting

2025-521880-10-00 Metastatic castrate resistant prostate cancer (mCRPC) 9 2026-02-16
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad… Recruiting

2025-521124-29-00 Non-Small Cell Lung Cancer 10 2026-02-13
A Study of JNJ-90301900 in Combination with Concurrent Chemoradiation Therapy in LA HNSCC Recruiting

2025-522914-22-00 Locally Advanced Head and Neck Squamous Cell Carcinoma 3 2026-02-11
A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E… Recruiting

2024-518777-34-00 B7-H4-Selected Advanced/Metastatic Endometrial Cancer. 5 2026-02-11
A Phase 1/2 clinical trial of DT-7012 as monotherapy and in combination with an immune checkpoint inhibitor in participants with selected ad… Recruiting

2025-523758-15-00 Cancer 7 2026-02-11
Phase 2 Study of INCB123667 in Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression Recruiting

2025-521513-14-00 Ovarian Cancer 4 2026-02-10
A study to assess the safety, tolerability, pharmacokinetic, pharmacodynamic, immunogenicity and antitumour activity of IPN60300 in adults w… Recruiting

2025-522139-33-00 Advanced or metastatic solid tumours 7 2026-02-10
C5951001- A Phase 1 Study of PF-08046876 in Participants with Advanced Solid Tumors. Recruiting

2025-521729-33-00 advanced solid tumors 1 2026-02-10
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity … Recruiting

2025-523165-19-00 Advanced, metastatic or unresectable solid tumors 1 2026-02-10
TulmiSTAR-02: Phase I/II open-label study of tulmimetostat in combination with darolutamide vs. darolutamide, and tulmimetostat with abirat… Recruiting

2025-521873-15-00 Metastatic hormone-sensitive prostate cancer 9 2026-02-09
Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated… Recruiting

2024-515948-23-00 Advanced pulmonary or gastroenteropancreatic poorly dif 5 2026-02-06
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Part… Recruiting

2025-522151-26-00 Advanced or Metastatic Non-Small-Cell Lung Cancer With 5 2026-02-06
To Study the Effect of Inavolisib in Combination with Fulvestrant in Participants with Breast Cancer Recruiting

2025-522805-39-00 Phosphatidylinositol-4,5-bisphosphate 3-kinase catalyti 4 2026-02-06
STOP VEN-IPC 2024-001 DE-ESCALATION STUDY EVALUATING VENETOCLAX AND AZACITIDINE DISCONTINUATION IN AML RESPONDING PATIENTS Recruiting

2024-514112-28-00 acute myeloid leukemia 4 2026-02-04